Vesugen

guinea pig

Also seen as: KED, Lys-Glu-Asp, vascular peptide bioregulator

The Dose Guy’s verdict

Sep 1, 2026
2 sources

A vascular bioregulator peptide with barely anything behind it. Vesugen has cell studies, one 32-person aging study that raises as many questions as it answers, and no controlled trial. If you are looking at vascular health, every standard intervention from exercise to blood-pressure management has a thousand times the evidence base. Vesugen is a curiosity, not a tool.

Would I take it?Not enough to act on.

What it is

Vesugen is a three-amino-acid synthetic peptide, Lys-Glu-Asp, from the Khavinson bioregulator family. The target is vascular endothelium, the cells that line your blood vessels. In cell culture it stimulates the proliferation marker Ki-67 in vascular endothelial cells. In a separate experiment, the same lab found vesugen’s effects on differentiation factors were more pronounced in aged prostatic fibroblasts than in young ones, the bioregulator pitch that the peptide finds tissue that needs repair.

Among its siblings, vesugen sits near the bottom for evidence. Thymalin has human studies and decades of clinical use. Vilon has conflicting animal data. Vesugen has one small report and bench work.

What the research shows

One reported human study and cell-level mechanism work. That is the file:

In a reported study of 32 people aged 41 to 83 with polymorbidity, vesugen showed a more visible geroprophylactic effect than pinealon by biological-age indicators, but prooxidant activity was recorded during combined treatment with vesugen and pinealon.Adv Gerontol 2015 · clinical · n=32

Vesugen and the peptide D-7 stimulated the proliferation-associated protein Ki-67 in tissue-specific cultures and dissociated vascular endothelial cells. Molecular docking placed both peptides at the MKI67 core promoter.Adv Gerontol 2014 · in vitro

No randomized controlled trial of vesugen and no placebo-controlled estimate of its clinical efficacy exists in the published literature.as of Aug 2026

Realistic protocols

I am not building a protocol around one 32-person study and some cell assays. The community runs vesugen the same way it runs all Khavinson bioregulators: short courses of subcutaneous injections, typically a few hundred micrograms daily for 10 to 20 days, then months off. If you run it, go low, go short, and understand the vascular-health story is a hypothesis, not a finding.

Side effects

One small study is the only source of human safety signals, and what it found is not reassuring:

monitorThe one human report found prooxidant activity and decreased CD34-positive stem-cell markers during combined treatment with vesugen and pinealon. Neither finding is explained or followed up.

anecdotalInjection-site reactions, the generic bioregulator complaint.

unknownNo adverse-event rates have been measured in any trial. One study flagging prooxidant signals in a vascular peptide is not reassuring.

Where to buy

No live listings from tracked vendors right now.